From: Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17–30 months
Group
Min
1st Quartile
Median
Mean
3rd Quartile
Max
Continued
17
21
25
25.23
29
30
Stopped
1
6
8
8.61
11
24